Organon & Co. buys biosimilar from Biogen for an undisclosed sum
HQ Team April 2, 2025: Organon has acquired the commercial rights for a biosimilar for intravenous infusion in treating arthritis and Covid-19 from.
Drugs
Medical
Pharma